Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.39 |
| ▸ | DEPTOR | Q8TB45 | 1/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | C1R | P00736 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1947913 | 0.84 | MEN1 (0.60) | MEN1ALOX15KMT2AHSD11B1DAGLA | |
| SCHEMBL1951090 | 0.79 | MEN1 (0.44) | MEN1ALOX15KMT2AHSD11B1DAGLA | |
| SCHEMBL1950740 | 0.79 | KMT2A (0.44) | MEN1ALOX15KMT2AHSD11B1DAGLA | |
| SCHEMBL12546697 | 0.78 | ALDH1A1 (0.47) | MEN1ALOX15KMT2ADAGLANR1H4 | |
| SCHEMBL12546583 | 0.77 | KMT2A (0.43) | MEN1ALOX15KMT2ADAGLANR1H4 | |
| SCHEMBL12546649 | 0.77 | MEN1 (0.43) | MEN1ALOX15KMT2AHSD11B1DAGLA | |
| SCHEMBL1948848 | 0.71 | MEN1 (0.59) | MEN1ALOX15KMT2AHSD11B1HTR2A | |
| SCHEMBL1951213 | 0.69 | ALDH1A1 (0.44) | HSD11B1DEPTOR | |
| SCHEMBL10996635 | 0.69 | ELANE (0.43) | HSD11B1DEPTOR | |
| SCHEMBL8778253 | 0.68 | ELANE (0.46) | HSD11B1DEPTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | claimed |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | claimed |
| EP-2509942-A2 | BIS-ACYLATED HYDROXYLAMINE DERIVATIVES | Johns Hopkins University (US) | 2012-10-17 | — | — | EP | claimed |
| WO-2011071947-A2 | BIS-ACYLATED HYDROXYLAMINE DERIVATIVES | JOHNS HOPKINS UNIVERSITY (US) | 2011-06-16 | — | — | WO | claimed |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | claimed |
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| US-9018411-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018411-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018411-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| WO-2011071947-A2 | BIS-ACYLATED HYDROXYLAMINE DERIVATIVES | JOHNS HOPKINS UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | disclosed |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | disclosed |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | MEN1 3253/4885ALOX15 545/4885KMT2A 580/4885 |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | MEN1 3253/4885ALOX15 545/4885KMT2A 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.